PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
https://doi.org/10.30895/2312-7821-2023-11-4-473-474
Abstract
This article is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews. Original publication: Schmidt AF, Carter J-PL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas J. PCSK9 monoclonal antibodies for the primary and secon dary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2020, Issue 10. Art. No.: CD011748. https://doi.org/10.1002/14651858.CD011748.pub3
Review
For citations:
PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease. Safety and Risk of Pharmacotherapy. 2023;11(4):473-474. (In Russ.) https://doi.org/10.30895/2312-7821-2023-11-4-473-474